Literature DB >> 2938667

Short- and long-term consequences of intracranial injections of the excitotoxin, quinolinic acid, as evidenced by GFA immunohistochemistry of astrocytes.

H Björklund, L Olson, D Dahl, R Schwarcz.   

Abstract

Astroglial reactions to intrastriatal and intrahypothalamic injections of the endogenous excitotoxin quinolinic acid (50 micrograms in 1 microliter) were studied in adult rats, using immunohistochemistry with antiserum to glial fibrillary acidic protein. Animals were sacrificed 6 h, 24 h, 3, 7 and 30 days or 1 year after the injection. Six and 24 h after quinolinic acid, the amount of glial fibrillary acidic protein-like immunoreactivity in the injected striatum was lower than in controls but returned to a normal level at 3 days. Not until 7 days was a clear striatal gliosis apparent, as evidenced by an increased density of glial fibrillary acidic protein-positive structures and brightly fluorescent, clearly hypertrophic cells. This gliosis was even more developed in animals sacrificed 30 days postoperatively. A weak astrocytic reaction was also observed in the ipsilateral corpus callosum at 6 h after quinolinic acid. By 3 days, a marked gliosis restricted to the injected hemisphere was present throughout corpus callosum and cortex cerebri. In animals sacrificed 30 days after quinolinic acid the extrastriatal astrocytic reaction was clearly diminished, although the striatal gliosis was still prominent. One year postinjection, no obvious gliosis could be observed in cortex cerebri or corpus callosum while striatal tissue, now markedly reduced in volume, was clearly gliotic. Using neurofilament antiserum, increased fluorescence intensity was noted in striatal nerve bundles during the first day after an intrastriatal quinolinic acid injection and persisted 1 year postoperatively. Controls were similarly injected with an equimolar amount of nicotinic acid, the non-excitatory, non-neurotoxic decarboxylation product of quinolinic acid. No changes in immunoreactivity of glial fibrillary acidic protein or neurofilament were found in these animals. In animals treated intrahypothalamically, a spherical central area almost devoid of glial fibrillary acidic protein-immunoreactivity was noted around the injection site 7 days after quinolinic acid administration. Around this area, gliosis was observed. Apart from a very restricted gliotic reaction around the needle tract, no astrocytic reaction was observed in nicotinic acid-injected control animals. We conclude that quinolinic acid causes both reversible and long-lasting gliosis when injected into the rat striatum. As a natural brain metabolite, quinolinic acid may constitute a particularly valuable tool for the elucidation of a possible role of glia in neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2938667     DOI: 10.1016/0006-8993(86)90362-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Xanthurenic Acid Formation from 3-Hydroxykynurenine in the Mammalian Brain: Neurochemical Characterization and Physiological Effects.

Authors:  K V Sathyasaikumar; M Tararina; H-Q Wu; S A Neale; F Weisz; T E Salt; R Schwarcz
Journal:  Neuroscience       Date:  2017-10-12       Impact factor: 3.590

2.  Personalized Needles for Microinjections in the Rodent Brain.

Authors:  Giovanna Paolone; Chiara Falcicchia; Gianluca Verlengia; Mario Barbieri; Anna Binaschi; Federico Paliotto; Beatrice Paradiso; Marie Soukupova; Silvia Zucchini; Michele Simonato
Journal:  J Vis Exp       Date:  2018-01-24       Impact factor: 1.355

3.  Progressive reparative gliosis in aged hosts and interferences with neural grafts in an animal model of Huntington's disease.

Authors:  Yvona Mazurová; Ivan Látr; Jan Osterreicher; Ivana Guncová
Journal:  Cell Mol Neurobiol       Date:  2006-06-14       Impact factor: 5.046

Review 4.  Involvement of quinolinic acid in AIDS dementia complex.

Authors:  Gilles J Guillemin; Stephen J Kerr; Bruce J Brew
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

5.  Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury.

Authors:  R Töpper; J Gehrmann; R Banati; M Schwarz; F Block; J Noth; G W Kreutzberg
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 6.  The involvement of astrocytes and kynurenine pathway in Alzheimer's disease.

Authors:  Ka Ka Ting; Bruce Brew; Gilles Guillemin
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

7.  ARPP-39, a membrane-associated substrate for cyclic AMP-dependent protein kinase present in neostriatal neurons.

Authors:  S I Walaas; P Greengard
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

Review 8.  Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.

Authors:  Robert Schwarcz; Paolo Guidetti; Korrapati V Sathyasaikumar; Paul J Muchowski
Journal:  Prog Neurobiol       Date:  2009-04-24       Impact factor: 11.685

9.  On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo.

Authors:  Laura Amori; Paolo Guidetti; Roberto Pellicciari; Yasushi Kajii; Robert Schwarcz
Journal:  J Neurochem       Date:  2009-02-06       Impact factor: 5.372

10.  Striatal implants protect the host striatum against quinolinic acid toxicity.

Authors:  S H Pearlman; M Levivier; T J Collier; J R Sladek; D M Gash
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.